Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Receivables - Accured (2020 - 2023)

Silo Pharma's Receivables - Accured history spans 4 years, with the latest figure at $9600.0 for Q3 2023.

  • For Q3 2023, Receivables - Accured rose 100.0% year-over-year to $9600.0; the TTM value through Sep 2023 reached $9600.0, up 100.0%, while the annual FY2022 figure was $6010.0, 396.69% up from the prior year.
  • Receivables - Accured for Q3 2023 was $9600.0 at Silo Pharma, up from $8390.0 in the prior quarter.
  • Across five years, Revenue - Other topped out at $85733.0 in Q1 2022 and bottomed at $3000.0 in Q2 2020.
  • The 4-year median for Receivables - Accured is $6160.0 (2021), against an average of $8445.9.
  • The largest annual shift saw Receivables - Accured tumbled 77.9% in 2021 before it soared 200.46% in 2023.
  • A 4-year view of Receivables - Accured shows it stood at $27876.0 in 2020, then crashed by 77.9% to $6160.0 in 2021, then dropped by 2.44% to $6010.0 in 2022, then soared by 59.73% to $9600.0 in 2023.
  • Per Business Quant, the three most recent readings for SILO's Receivables - Accured are $9600.0 (Q3 2023), $8390.0 (Q2 2023), and $7193.0 (Q1 2023).